Description
Injectran Pharmacodynamics
Chondroitin sulfate – the main component of proteoglycans, which together with collagen fibers make up the cartilage matrix.
Pharmacodynamics
Provides chondrostimulating, regenerating, anti-inflammatory and analgesic effect. Chondroitin sulfate is involved in the construction of the basic substance of cartilage and bone tissue. It has chondroprotective properties, enhances metabolic processes in hyaline and fibrous cartilage and subchondral bone, inhibits the activity of enzymes that cause degradation (destruction) of articular cartilage, stimulates the production of proteoglycans by chondrocytes, affects the calcium-phosphorus metabolism in cartilage tissue, stimulates its regeneration, and participates in the construction of bone and cartilage base substance. It has anti-inflammatory and analgesic properties, reduces the release into the synovial fluid of inflammatory mediators and pain factors through synoviocytes and synovial macrophages, inhibits the secretion of leukotrienes and prostaglandins. The drug prevents the degeneration of connective tissue, reduces calcium loss, and accelerates bone repair.
Chondroitin sulfate slows the progression of osteoarthritis and osteochondrosis. Helps restore the joint capsule and cartilage surfaces of joints, prevents collapse of connective tissue, normalizes the production of joint fluid.
The clinical effect is manifested by improved joint mobility, decreased intensity of pain, and the therapeutic effect persists for a long time after the end of therapy. In the treatment of degenerative changes in the joints, accompanied by secondary synovitis, the effect is observed in 2-3 weeks from the start of the course.
Having structural similarity with heparin, it can potentially prevent the formation of fibrin clots in the synovial and subchondral microcirculatory bed.
Indications
Degenerative-dystrophic diseases of the joints and spine:
– osteoarthritis of the peripheral joints;
– Intervertebral osteochondrosis and osteoarthritis.
To accelerate the formation of the bone callus at fractures.
Contraindications
. Hypersensitivity to chondroitin sulfate;
– Bleeding, a tendency to bleeding;
– thrombophlebitis;
– Pregnancy, breast-feeding (breast-feeding should be discontinued during treatment);
– Children (data on efficacy and safety are not available).
Administration during pregnancy and lactation
Use of the drug INECTRAN during pregnancy is contraindicated.
In case of using the drug during breast-feeding, breast-feeding should be discontinued.
- Dosage and administration method
Intramuscularly, 1 ml every other day. If tolerated, the dose is increased to 2 ml, starting with the fourth injection. The course of treatment is 25-35 injections. If necessary, a second course of treatment may be carried out after 6 months. Duration of repeated courses of treatment is set by the doctor. - For the formation of the bone callus treatment course is 3-4 weeks (10-14 injections a day).
